The draft proposes nine new entries and revisions to 18 existing entries for medicinal crude drugs not listed in the Japanese Pharmacopoeia. Comments must arrive by November 4. The standards are not finalized.
Published: 2026-10-06Comments due November 4 (closes November 5 at 00:00 JST)
Official title and status
日本薬局方外生薬規格2026(案)に関する御意見の募集について
Public consultation · draft
The draft covers crude drugs used as medicine ingredients, not only OTC medicines.
Checked October 6, 2026: case page, submission instructions and overview; the full annex has not been reviewed line by line.
The list dated September 1 records loxoprofen as Class 1, with a request for designated Class 2. It is not an announcement that the change has taken effect.
Document as-of date: 2026-09-01
Document details and status
一般用医薬品のリスク区分変更に関する要望申出状況
Document number: Not confirmed
Status in the source: 要望・審議情報(変更施行の告知ではありません)
Check subsequent amendments as well; this document alone may not describe all currently applicable rules.
Explains eligibility, submission and the subsequent evidence and committee-review process. A request or review does not itself change a medicine’s sales classification.
Date shown in document: 2026-04-01
Document details and status
一般用医薬品のリスク区分変更に関する要望受付について
Document number: Not confirmed
Status in the source: Request-process guidance, not a product reclassification
Check subsequent amendments as well; this document alone may not describe all currently applicable rules.
Sets out purchase checks, information provision, display arrangements and procedures. Ingredient designations and quantity thresholds are left to later notices, so this document alone does not identify every covered product.
Material for the 25 December 2025 insurance-policy meetings describing the proposed scope, charge and consideration of exemptions. Included as policy-development background rather than current implementation guidance.
Date shown in document: 2025-12-25Meeting date: 2025-12-25
Document details and status
OTC類似薬を含む薬剤自己負担の見直しの在り方について
Document number: Not confirmed
Status in the source: Historical discussion material preceding later implementation rules
Check subsequent amendments as well; this document alone may not describe all currently applicable rules.
Explains ordinance changes for online pharmacist guidance and sales of designated abuse-prevention medicines. The notice states commencement on 1 May 2026.
Explains ongoing candidate requests from professional societies, organizations, companies and consumers. The evaluation process considers needs, medical-use experience, challenges and possible safeguards.
Date shown in document: 2025-04-22
Document details and status
スイッチOTC医薬品の候補となる成分の要望募集について
Document number: Not confirmed
Status in the source: Candidate-request guidance, not approval or launch confirmation
Check subsequent amendments as well; this document alone may not describe all currently applicable rules.
Contains deliberation results, the review report and a correction sheet for Pariet S and Pariet 10. The deliberation report modifies the indications and specifies at least three years of post-marketing surveillance after approval.
Issued: 2025-01-27
Document details and status
審議結果報告書(パリエットS、パリエット10/ラベプラゾールナトリウム)
Document number: Not confirmed
Status in the source: Historical review and deliberation documents, not current product labeling
Check subsequent amendments as well; this document alone may not describe all currently applicable rules.
A 2023 sales-system committee document explaining medicine categories, the prescription-based supply principle and the exceptional-sales framework at that time.
Date shown in document: 2023-02-22Meeting date: 2023-02-22
Document details and status
処方箋医薬品以外の医療用医薬品の販売について
Document number: Not confirmed
Status in the source: Historical discussion material; subsequent amendments not checked
Check subsequent amendments as well; this document alone may not describe all currently applicable rules.
Organizes issues involving drug and disease characteristics, appropriate use, sales systems and stakeholder roles. The report is dated 2 February 2021; its circulation notice is dated 8 February.
Issued: 2021-02-08Date shown in document: 2021-02-02
Document details and status
医療用から要指導・一般用への転用に関する評価検討会議における中間とりまとめについて
Document number: 薬生薬審発0208第8号(別添写し:同第7号)
Status in the source: Historical foundational material; later revisions not checked
Check subsequent amendments as well; this document alone may not describe all currently applicable rules.